What Causes Irregular Periods in Your 40s? Perimenopause Explained

The Biology Behind Perimenopausal Cycle Changes

Perimenopause begins when the finite pool of ovarian follicles drops below a threshold that can no longer sustain regular monthly ovulation. The result is a hormonal environment defined by inconsistency: estradiol may spike to levels higher than peak reproductive values one month, then plummet the next.

The Study of Women's Health Across the Nation (SWAN), a longitudinal cohort that followed 3,302 women through the menopausal transition, documented that cycle irregularity is the earliest reliable marker of perimenopause, appearing a median of 6 to 7 years before the final menstrual period [1]. During early perimenopause, the pituitary gland increases follicle-stimulating hormone (FSH) output in an attempt to recruit follicles that are becoming increasingly resistant to stimulation. This FSH rise is not steady. A single blood draw may catch a normal value one week and an elevated one two weeks later, which is why the Endocrine Society's 2015 clinical practice guideline advises against using isolated FSH levels to diagnose perimenopause [2].

Progesterone is the hormone most consistently affected. Without reliable ovulation, the corpus luteum fails to form, and progesterone production drops. The clinical consequence: an estrogen-dominant environment that thickens the endometrial lining unevenly, producing cycles that are sometimes heavy, sometimes scanty, and sometimes absent. A 2012 analysis published in the Journal of Clinical Endocrinology & Metabolism found that anovulatory cycles increase from roughly 2% to 3% of cycles in the mid-30s to over 50% of cycles by the late perimenopausal stage [3].

How Cycle Patterns Actually Change

The textbook image of periods simply "tapering off" before menopause does not match clinical reality. Cycles change in multiple directions, often within the same year, and no two women follow the same trajectory.

SWAN data showed three dominant patterns during the early transition [1]. Some women experienced a shortening of cycle length to 21 to 24 days, driven by a truncated follicular phase as remaining follicles are recruited faster. Others saw cycles stretch to 36 to 60 days when follicle recruitment stalled entirely for a month. A third group alternated between these extremes unpredictably.

Heavy menstrual bleeding (HMB) is particularly common. A SWAN sub-study published in the American Journal of Epidemiology found that 77.7% of perimenopausal women reported at least three episodes of heavy bleeding (defined as 80 mL or more per cycle) over three years of follow-up [4]. The bleeding can be alarming enough to prompt emergency department visits. One large Kaiser Permanente study noted that perimenopause-related abnormal uterine bleeding accounts for a significant proportion of gynecologic ED presentations in women aged 40 to 55 [5].

Spotting between periods is another frequent complaint. Mid-cycle spotting can reflect a late-breaking attempt at ovulation, endometrial instability from unopposed estrogen, or structural causes like polyps. The distinction matters for clinical management.

Ruling Out Other Causes

Perimenopause is the most likely explanation for irregular cycles after 40, but it is not the only one. A responsible workup considers several conditions that overlap in age of presentation.

Thyroid disease affects roughly 5% of women aged 35 to 65 and can cause cycle irregularity that mimics perimenopause exactly [6]. Both hypothyroidism and hyperthyroidism alter menstrual patterns. A TSH level is the minimum screening test recommended by the American College of Obstetricians and Gynecologists (ACOG) for any woman presenting with new-onset cycle changes [7].

Uterine fibroids are present in up to 70% of white women and over 80% of Black women by age 50 [8]. While fibroids themselves do not cause cycle irregularity in the traditional sense (they more often cause heavy or prolonged bleeding on a regular schedule), submucosal fibroids can produce intermenstrual bleeding easily confused with irregular periods.

Endometrial polyps become more common with age and carry a small but clinically meaningful risk of harboring atypical hyperplasia or early endometrial cancer. The risk of malignancy in endometrial polyps rises from about 1.5% premenopausally to 5.4% in postmenopausal women, making evaluation appropriate when bleeding patterns are atypical [9].

Polycystic ovary syndrome (PCOS) may persist into the 40s and should not be overlooked. Hyperprolactinemia, Cushing syndrome, and premature ovarian insufficiency are rarer causes that warrant consideration when the clinical picture does not fit straightforward perimenopause.

Diagnosis: What Testing Actually Helps

The diagnosis of perimenopause is primarily clinical. A woman over 40 with new cycle irregularity, vasomotor symptoms, or both meets the Stages of Reproductive Aging Workshop (STRAW+10) criteria for early or late menopausal transition without any lab work at all [10].

Targeted labs serve a specific purpose: excluding mimics. A reasonable initial panel includes TSH, prolactin, and a pregnancy test (pregnancy remains possible during perimenopause and is the most dangerous diagnosis to miss). An endometrial biopsy or transvaginal ultrasound is indicated when bleeding is persistently heavy, occurring more frequently than every 21 days, or when a woman has risk factors for endometrial hyperplasia (obesity, diabetes, chronic anovulation, tamoxifen use).

Anti-Mullerian hormone (AMH) has gained attention as a marker of ovarian reserve. A 2017 analysis of SWAN participants found that AMH levels below 0.20 ng/mL predicted the final menstrual period within approximately 5.99 years with reasonable accuracy [11]. AMH is more stable across the cycle than FSH, but it is not yet recommended as a standalone diagnostic tool for perimenopause by any major guideline body.

When Irregular Periods Signal Something More Serious

Not every change in cycle regularity is benign perimenopause. Specific red flags require prompt evaluation.

Bleeding that soaks through a pad or tampon every hour for more than two consecutive hours suggests a volume that may cause hemodynamic compromise. Intermenstrual bleeding lasting longer than three consecutive months, especially in women with BMI above 30, warrants endometrial assessment to exclude hyperplasia. Any bleeding that occurs after 12 months of amenorrhea is postmenopausal bleeding by definition and requires workup regardless of age.

The ACOG Practice Bulletin on Management of Abnormal Uterine Bleeding specifically recommends endometrial sampling for any woman over 45 with abnormal bleeding and for women under 45 who have risk factors for endometrial cancer [12]. An office endometrial biopsy has a sensitivity of 99.6% for detecting endometrial cancer in postmenopausal women, according to a meta-analysis published in Obstetrics & Gynecology [13].

Postcoital bleeding (after intercourse) raises concern for cervical pathology and warrants visualization of the cervix with appropriate testing. New-onset pelvic pain accompanying cycle changes may indicate endometriosis progression, adenomyosis, or an ovarian mass.

Treatment Options for Perimenopausal Cycle Irregularity

Treatment depends on what bothers the patient most and where she sits in the STRAW+10 staging system. The options range from observation to systemic hormone therapy.

Combined oral contraceptives (COCs) remain a first-line option for early perimenopausal women who want cycle control, contraception, and symptom relief in a single intervention. Low-dose formulations (20 mcg ethinyl estradiol) suppress erratic ovarian function, regulate withdrawal bleeding, and reduce hot flashes. The 2022 North American Menopause Society (NAMS) position statement supports COC use in healthy, non-smoking women up to age 50 for this purpose [14].

Cyclic progestins are appropriate for women who do not need contraception but want predictable bleeding. Medroxyprogesterone acetate 10 mg for 12 to 14 days per month induces a predictable withdrawal bleed and protects the endometrium from unopposed estrogen. Micronized progesterone (Prometrium) 200 mg cyclically offers a bioidentical alternative with a more favorable lipid profile, as shown in the PEPI trial [15].

Levonorgestrel intrauterine system (LNG-IUS): The 52 mg LNG-IUS (Mirena) is highly effective for managing heavy perimenopausal bleeding. A randomized trial published in the New England Journal of Medicine in 2013 found that the LNG-IUS was superior to usual medical treatment for heavy menstrual bleeding, with greater improvement in quality of life at 2 years [16].

Menopausal hormone therapy (MHT) becomes the appropriate option once a woman has clearly transitioned to late perimenopause or early postmenopause and vasomotor symptoms dominate. Transdermal estradiol (0.025 to 0.05 mg/day) combined with micronized progesterone carries the most favorable risk profile for women under 60 or within 10 years of menopause, per the 2017 Endocrine Society guideline on MHT [17].

Dr. Stephanie Faubion, Medical Director of NAMS, has stated: "The perimenopausal transition is a window where targeted hormonal management can significantly improve quality of life while the benefit-risk ratio is most favorable."

Lifestyle Factors That Influence Perimenopausal Bleeding

Hormones are not the only variable. Body composition, stress, and exercise patterns all modify the perimenopausal bleeding experience.

Adipose tissue produces estrone through aromatase activity, and higher BMI correlates with heavier and more prolonged bleeding during perimenopause. SWAN data confirmed that women with BMI above 35 experienced 50% more days of bleeding per year compared to normal-weight peers [4]. Weight management through even modest caloric adjustment (a 5% to 7% reduction in body weight) can measurably reduce menstrual blood loss.

High-intensity exercise in excess of 7 hours per week may suppress the hypothalamic-pituitary-ovarian axis enough to alter cycle patterns independently of perimenopause. For most women, 150 minutes per week of moderate aerobic exercise, the minimum recommended by the CDC physical activity guidelines, supports metabolic health without suppressing ovulation [18].

Chronic psychological stress elevates cortisol, which can inhibit GnRH pulsatility and amplify cycle irregularity. A 2004 study in Psychosomatic Medicine found that perceived stress was independently associated with longer and more variable menstrual cycles [19]. The clinical advice is not simply "reduce stress" but rather to identify a specific, sustainable practice (cognitive behavioral therapy, scheduled physical activity, or structured sleep hygiene) that reduces cortisol exposure.

Contraception Still Matters

A common and dangerous assumption is that irregular periods mean infertility. They do not. Ovulation can occur sporadically throughout perimenopause, and pregnancies in women over 40 carry higher risks of gestational diabetes, preeclampsia, chromosomal abnormalities, and cesarean delivery.

The CDC's U.S. Medical Eligibility Criteria for Contraceptive Use affirms that most contraceptive methods remain category 1 (no restriction) or category 2 (advantages outweigh risks) for healthy women over 40 [20]. The LNG-IUS is particularly efficient in this population because it simultaneously manages bleeding and provides contraception.

Contraception should continue until 12 consecutive months of amenorrhea confirm menopause. For women on COCs, the pill itself masks the final menstrual period, so a trial off hormones (or a serum FSH drawn during the placebo week) may be necessary to confirm menopausal status.

Dr. Andrew Kaunitz, Professor of Obstetrics and Gynecology at the University of Florida, has noted: "We see unintended pregnancies in perimenopausal women every year because both patients and clinicians assume irregular cycles mean contraception is no longer needed."

The STRAW+10 Staging System

The Stages of Reproductive Aging Workshop, updated in 2011 as STRAW+10, provides the most widely accepted framework for categorizing the menopausal transition [10]. Understanding the staging system helps clinicians match treatment intensity to transition phase.

Stage -2 (Early transition): Cycle length varies by 7 or more days from the woman's established baseline in consecutive cycles. Elevated FSH (above 25 IU/L) may be present. Most women notice the first "something is different" signal here.

Stage -1 (Late transition): Intervals of amenorrhea lasting 60 or more days appear. Anovulatory cycles predominate. Vasomotor symptoms intensify. This stage lasts 1 to 3 years on average and is the period of highest symptom burden.

Stage +1a (Early postmenopause): Defined as the first 2 years after the final menstrual period. FSH continues to rise; estradiol reaches its nadir. Vasomotor symptoms peak during this window. Bone loss accelerates at a rate of approximately 2% to 3% per year at the spine, per longitudinal SWAN bone density data [21].

The practical value of STRAW+10 is in treatment sequencing. COCs and cyclic progestins fit stages -2 and -1. MHT with transdermal estradiol becomes appropriate at stage -1 through +1. This staging prevents premature escalation or delayed intervention.

What to Expect From Your Doctor Visit

A woman in her 40s presenting with cycle changes should expect a focused history, a pelvic exam, and selected labs. The visit does not need to be complicated.

The history should cover cycle length and flow over the past 6 to 12 months (a period-tracking app is genuinely useful here), vasomotor symptoms, sexual function changes, mood shifts, and family history of early menopause. Physical exam includes a pelvic exam with Pap smear if due and assessment for thyromegaly.

Labs: TSH, CBC (to check for anemia if bleeding is heavy), pregnancy test. FSH and estradiol are optional and most useful when drawn on cycle day 2 to 5 if periods are still occurring. Transvaginal ultrasound is indicated if the exam suggests fibroids, if bleeding is heavy, or if the endometrial lining needs measurement. Endometrial biopsy is indicated per the ACOG criteria described above [12].

The single most valuable thing a patient can bring to this visit is 3 to 6 months of cycle-tracking data with flow volume estimates (light, moderate, heavy, or number of products used per day). This data converts a vague complaint into actionable clinical information.